Clemedi Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $5.17M

  • Investors
  • 5

Clemedi General Information

Description

Developer of a disease management platform designed to render comprehensive information for targeted therapy. The company's platform combines DNA sequencing with machine learning algorithms that slow the spread of antibiotic resistance and save current antibiotics for future generations, enabling doctors to treat infectious diseases better by reducing antibiotic consumption and the spread of further resistance.

Contact Information

Website
www.clemedi.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Wagistrasse 12
  • 8952 Schlieren
  • Switzerland
+41 043
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Big Data, Artificial Intelligence & Machine Learning, HealthTech, Life Sciences
Corporate Office
  • Wagistrasse 12
  • 8952 Schlieren
  • Switzerland
+41 043

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Clemedi Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC $5.17M Completed Generating Revenue
6. Angel (individual) 09-Jul-2021 Completed Generating Revenue
5. Grant 26-Jul-2019 Completed Generating Revenue
4. Accelerator/Incubator 15-May-2019 Completed Generating Revenue
3. Accelerator/Incubator 20-Jun-2018 Completed Generating Revenue
2. Grant 27-Feb-2018 $10.7K Completed Generating Revenue
1. Accelerator/Incubator 17-Aug-2017 Completed Generating Revenue
To view Clemedi’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Clemedi Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Clemedi Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Horizon 2020 Government
MassChallenge Accelerator/Incubator
Science4Life Accelerator/Incubator
Venture Kick Accelerator/Incubator
EIT Health Accelerator/Incubator
To view Clemedi’s complete investors history, request access »

Ready to get started?

Request a free trial

Clemedi FAQs

  • When was Clemedi founded?

    Clemedi was founded in 2016.

  • Where is Clemedi headquartered?

    Clemedi is headquartered in Schlieren, Switzerland.

  • What is the size of Clemedi?

    Clemedi has 8 total employees.

  • What industry is Clemedi in?

    Clemedi’s primary industry is Diagnostic Equipment.

  • Is Clemedi a private or public company?

    Clemedi is a Private company.

  • What is Clemedi’s current revenue?

    The current revenue for Clemedi is .

  • How much funding has Clemedi raised over time?

    Clemedi has raised $5.17M.

  • Who are Clemedi’s investors?

    Horizon 2020, MassChallenge, Science4Life, Venture Kick, and EIT Health have invested in Clemedi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process